PhasED-Seq^TM is a liquid-biopsy powered platform that detects minimal residual disease (MRD) from circulating tumor DNA (ctDNA), an early indicator of cancer relapse. Available for solid tumors, B-cell lymphomas, and multiple myeloma. 

 ... More Info Less Info

Foresight CLARITY is a liquid-biopsy platform designed to confidently detect the presence of minimal residual disease (MRD) from circulating tumor DNA (ctDNA) with unprecedented sensitivity across multiple cancers. Predict response and recurrence earlier and with greater accuracy compared to radiographic imaging and other liquid-biopsy methods. 

Foresight CLARITY is powered by PhasED-Seq, our proprietary, patented and peer-reviewed phased-variant detection technology developed by our founders. PhasED-Seq monitors tumor-specific and patient-specific phased variants, which are two or more SNVs (single nucleotide variants) that occur within a defined proximity on the same DNA molecule. Utilizing phased variants greatly reduces the background noise/error rate, which allows us to deliver a highly accurate MRD test. 
 ... More Info Less Info